American Century Companies Inc. Purchases 8,359 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

American Century Companies Inc. raised its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 8.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 107,862 shares of the company’s stock after acquiring an additional 8,359 shares during the quarter. American Century Companies Inc.’s holdings in ORIC Pharmaceuticals were worth $870,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Geode Capital Management LLC grew its stake in shares of ORIC Pharmaceuticals by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,273,513 shares of the company’s stock valued at $13,056,000 after purchasing an additional 50,821 shares during the period. Franklin Resources Inc. grew its holdings in ORIC Pharmaceuticals by 26.1% during the 3rd quarter. Franklin Resources Inc. now owns 950,459 shares of the company’s stock worth $9,067,000 after acquiring an additional 196,804 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in ORIC Pharmaceuticals by 1.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 417,955 shares of the company’s stock worth $3,373,000 after buying an additional 7,726 shares during the last quarter. Wellington Management Group LLP increased its position in shares of ORIC Pharmaceuticals by 42.0% in the 3rd quarter. Wellington Management Group LLP now owns 174,388 shares of the company’s stock valued at $1,787,000 after buying an additional 51,565 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its stake in ORIC Pharmaceuticals by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 162,909 shares of the company’s stock valued at $1,315,000 after buying an additional 24,947 shares in the last quarter. Institutional investors own 95.05% of the company’s stock.

ORIC Pharmaceuticals Stock Performance

ORIC stock opened at $4.92 on Friday. ORIC Pharmaceuticals, Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.67. The stock’s 50 day simple moving average is $7.40 and its 200 day simple moving average is $8.67. The company has a market cap of $349.45 million, a P/E ratio of -2.70 and a beta of 1.38.

ORIC Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings results on Tuesday, February 18th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.01. Equities analysts predict that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Wedbush restated an “outperform” rating and issued a $20.00 price target on shares of ORIC Pharmaceuticals in a research note on Thursday, March 20th. JPMorgan Chase & Co. lifted their price objective on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Guggenheim reissued a “buy” rating on shares of ORIC Pharmaceuticals in a report on Wednesday, February 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of ORIC Pharmaceuticals in a research report on Friday, February 21st. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $18.86.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.